Introduction {#s2}
============

In recent years, the incidence of type 2 diabetes mellitus (DM) and chronic heart failure (CHF) has been increasing worldwide due to extended life expectancy or lifestyle changes. In addition, the condition of a number of patients was complicated with type 2 DM and CHF in clinics \[[@R01], [@R02]\]. Some basic and clinical studies have shown that cardiac function is affected by DM due to various factors, including high blood glucose levels, insulin resistance, renin-angiotensin system, or other problems \[[@R03], [@R04]\]. Furthermore, some studies have reported that patients with type 2 DM with HF had poor prognosis compared with those without DM and with a history of HF \[[@R05], [@R06]\]. Therefore, considering adequate diagnosis and therapy for patients with type 2 DM with CHF is important.

Advanced glycation end products (AGEs) play an important role in the pathophisiology of DM. Among the methods used to evaluate AGEs, skin autofluorescence (AF) is known to be a simple and reliable marker of AGEs *in vivo*, and recent clinical studies have indicated that skin AF levels are significantly associated with diabetic complications, such as macro- or microvascular disease \[[@R07]-[@R9]\]. However, data regarding the relationships between skin AF and pathogenesis of CHF are limited. Therefore, this cross-sectional study attempted to clarify the clinical significance of skin AF in patients with type 2 DM with CHF.

Materials and Methods {#s3}
=====================

Patients {#s3a}
--------

A total of 257 outpatients were enroolied between November 2013 and October 2017 with type 2 DM with CHF who had medical treatment at the Hitsumoto Medical Clinic. CHF was defined based on ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults \[[@R10]\]. The patients included 96 (37.8%) and 161 (62.2%) men and women, respectively, with a mean age of 79 ± 7 years (mean ± standard deviation). All participants provided informed consent, and the local ethics committee approved the study protocol.

Skin AF measurement {#s3b}
-------------------

Skin AF was measured using a commercial device (AGE Reader™; DiagnOptics, Groningen, the Netherlands), as previously described \[[@R11], [@R12]\]. AF was defined as the average light intensity per nanometer between 300 and 420 nm. Skin AF levels were expressed in arbitrary units (AU). All measurements were performed at the volar side of the lower arm, approximately 10 - 15 cm below the elbow, while the patients were in a sitting position. The value of pentosidine, a major component of AGEs, was measured using skin biopsy at the volar side of the lower arm and seemed to correlate with skin AF \[[@R13]\]. The validity and reliability of skin AF levels in the Japanese population measured using this method has been established previously \[[@R12]\].

Evaluation of clinical parameters {#s3c}
---------------------------------

Various clinical parameters such as classic risk factors of cardiovascular disease, history of ischemic heart disease, blood glucose-related parameters, echocardiographic findings, kidney function, brain natriuretic peptide (BNP) levels, high-sensitivity cardiac troponin T (hs-cTnT) levels, oxidative stress, and arterial function were evaluated. Obesity was identified using body mass index (BMI), calculated as the weight (kg) divided by the squared height (m^2^). Current smoking was defined as smoking at least one cigarette per day over the previous 28 days. History of ischemic heart disease was defined as patients with history of myocardial infarction and/or angiography-proven significant stenosis. Hypertension was defined as a systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or those taking antihypertensive medications. Dyslipidemia was defined as low-density lipoprotein cholesterol levels ≥ 140 mg/dL, high-density lipoprotein cholesterol levels ≤ 40 mg/dL, triglyceride levels ≥ 150 mg/dL, or based on an ongoing treatment for dyslipidemia. Glucose and insulin levels were measured using the glucose oxidase method and an enzyme immunoassay, respectively. To measure insulin resistance, HOMA-IR was calculated using the following equation \[[@R14]\]: HOMA-IR = fasting glucose concentration (mg/dL) × fasting insulin concentration (µg/mL)/405. The hemoglobin A1c levels were expressed using the National Glycohemoglobin Standardization Program. Standard technique for echocardiography was performed using HI VISION Avius (Hitachi Medical Corporation, Tokyo, Japan), and valvular heart disease was diagnosed based on the guideline of the Japanese Circulation Society (Guidelines for the Clinical Application of Echocardiography (JCS 2010)). Valvular heart disease consisted of aortic or mitral valve disease (aortic stenosis, aortic regurgitation, mitral stenosis, and mitral regurgitation). Left ventricular wall thickness, left ventricular extended period diameter, left ventricular ejection fraction, left atrial dimension, and E/e′ were also measured by echocardiography. The estimated glomerular filtration rate (eGFR) was calculated using the adjusted Modification of Diet in the Renal Disease Study equation, which was proposed by the working group of the Japanese Chronic Kidney Disease Initiative \[[@R15]\]. BNP levels were measured using a commercial kit (SHIONOSPOT Reader; Shionogi & Co., Osaka, Japan), and hs-cTnT levels were also measured using a commercial kit (Roche Diagnostics, Switzerland) \[[@R16]\]. As an oxidative stress maker *in vivo* \[[@R17]\], the reactive oxygen metabolite (d-ROM) test was performed using a commercial kit (Diacron, Grosseto, Italy). In this study, cardio-ankle vascular index (CAVI) as a physiological marker of arterial function was measured using a VaSera CAVI instrument (Fukuda Denshi, Tokyo, Japan), following the previously described methods \[[@R18]\]. Briefly, the brachial and ankle pulse waves were determined using inflatable cuffs, with the pressure maintained between 30 and 50 mm Hg to ensure that the cuff pressure had a minimal effect on systemic hemodynamics. Systemic blood and pulse pressures were simultaneously determined, with the participant in a supine position. CAVI was measured after a 10-min rest in a quiet room. The accuracy of CAVI is known to be less in the presence of non-sinus rhythm or obstructive arteriosclerosis. Therefore, patients with chronic atrial fibrillation and/or obstructive arteriosclerosis (ankle-brachial index \< 0.9) were excluded. The mean values of the left and right sides were used for statistical evaluation of the CAVI.

Statistical analysis {#s3d}
--------------------

All statistical analyses were performed using Stat View-J 5.0 (HULINKS, Tokyo, Japan). Data in the study were expressed as mean ± standard deviation. Between-group comparisons were performed using Student's *t*-test. Simple regression analysis was performed using the Spearman rank correlation, and a multivariate analysis was performed using multiple regression or multiple logistic regression analyses. P \< 0.05 was considered statistically significant.

Results {#s4}
=======

[Table 1](#T1){ref-type="table"} summarizes the patient characteristics. The mean skin AF levels were 2.8 ± 0.5 AU (range, 1.7 - 4.0 AU). In total, 60 patients (23%) had a history of hospitalization due to HF. [Figure 1](#F1){ref-type="fig"} shows the comparisons of skin AF levels between patients with and without a history of hospitalization due to HF. The skin AF levels in patients with a history of hospitalization due to HF were significantly higher than those without a history of hospitalization due to HF (3.0 ± 0.5 AU vs. 2.7 ± 0.5 AU, respectively, P \< 0.001), although the mean age was similar between the two groups. [Table 2](#T2){ref-type="table"} presents the correlations between skin AF and various clinical parameters. Age, smoking habits, presence of ischemic heart disease, HbA1c, left atrial dimension, E/e′, eGFR, BNP, hs-cTnT, d-ROMs test, and the CAVI were significantly correlated with skin AF. [Table 3](#T3){ref-type="table"} summarizes the results of a multiple regression analysis with skin AF as a subordinate factor. Explanatory factors were selected by examining multicollinearity among the variables or by conducting a stepwise method. Hs-cTnT, E/e′, history of hospitalization due to HF, CAVI, d-ROM test, and age were identified as independent variables when skin AF was used as a subordinate factor. The participants were divided into three groups based on their skin AF values, and a multiple logistic regression analysis was performed to describe the simple threshold of skin AF for detecting hospitalization due to HF or high hs-cTnT levels ([Fig. 2](#F2){ref-type="fig"}). Patients with high (≥ 3.0 AU) or moderate skin AF levels (2.6 - 2.9 AU) showed a significantly higher risk (OR, 3.2 (95% confidence interval (CI): 1.4 - 7.0), P \< 0.01; OR, 2.0 (95% CI: 1.1 - 4.0), P \< 0.05, respectively) of detecting hospitalization due to HF than those with low skin AF (≤ 2.5 AU). In contrast, patients with high or moderate ski AF levels had a significantly higher risk (OR, 7.8 (95% CI: 4.1 - 20.0), P \< 0.001; OR, 2.2 (95% CI: 1.1 - 4.3), P \< 0.05, respectively) of having a high hs-cTnT level (≥ 0.018 ng/mL) than did those with low skin AF.

###### Patient Characteristics

  ---------------------------------- --------------
  n (male/female)                    257 (96/161)
  Age (years)                        79 ± 7
  Skin autofluorescence (AU)         2.8 ± 0.5
  Body mass index                    22.8 ± 0.6
  Current smoker, n (%)              30 (12)
  Ischemic heart disease, n (%)      39 (15)
  HF hospitalization, n (%)          60 (23)
  Hypertension, n (%)                202 (79)
  Systolic blood pressure (mm Hg)    139 ± 17
  Diastolic blood pressure (mm Hg)   81 ± 10
  Dyslipidemia, n (%)                172 (67)
  Fasting blood glucose (mg/dL)      143 ± 26
  HOMA-IR                            2.8 ± 1.8
  Hemoglobin A1c (%)                 7.3 ± 1.0
  Heart valvular disease, n (%)      189 (74)
  IVSTd (mm)                         9.8 ± 1.8
  LVDd (mm)                          50.0 ± 3.6
  LVEF (%)                           68.8 ± 12.8
  LAD (mm)                           42.5 ± 5.6
  E/e′                               9.6 ± 3.7
  eGFR (mL/min/1.73 m^2^)            48.4 ± 17.6
  Log-BNP (pg/mL)                    2.0 ± 0.3
  Log-hs-cTnT (ng/mL)                -2.0 ± 0.3
  d-ROMs test (U. CARR)              336 ± 108
  CAVI                               9.7 ± 1.4
  Medication                         
    Sulfonylurea, n (%)              186 (72)
    Biguanide, n (%)                 41 (16)
    DPP-4 inhibitor, n (%)           155 (60)
    Insulin, n (%)                   26 (10)
    RAS inhibitor, n (%)             169 (66)
    β-blocker, n (%)                 56 (22)
    Diuretics, n (%)                 40 (16)
    Statin, n (%)                    159 (62)
  ---------------------------------- --------------

Continuous values are mean ± SD. HF: heart failure; HOMA-IR: homeostasis assessment insulin resistance; IVSTd: interventricular septal thickness at end-diastole; LVDd: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LAD: left atrial dimension; eGFR: estimated glomerular filtration rate; BNP: brain natriuretic peptide; hs-cTnT: high-sensitivity cardiac troponin T; d-ROMs: derivatives of reactive oxygen metabolites; CAVI: cardio-ankle vascular index; DPP: dipeptidyl peptidase; RAS: renin-angiotensin system.

![Comparisons of skin AF values between patients with and without history of heart failure admission. The skin AF levels in patients with a history of hospitalization due to HF were significantly higher than those without a history of hospitalization due to HF (3.0 ± 0.5 AU vs. 2.7 ± 0.5 AU, respectively, P \< 0.001) even though mean age was similar between the two groups (80 ± 7 years vs. 79 ± 7 years, respectively). \*P \< 0.001 vs. non-history of HF hospitalization. AF: autofluorescence; HF: heart failure; AU: arbitrary units.](cr-09-083-g001){#F1}

###### Relationship Between Skin AF and Various Clinical Parameters

                                             r       P value
  ------------------------------------------ ------- ----------
  Sex (female = 0, male = 1)                 -0.01   0.065
  Age                                        0.12    \< 0.05
  Body mass index                            0.06    0.363
  Current smoker (no = 0, yes = 1)           0.12    \< 0.05
  Ischemic heart disease (no = 0, yes = 1)   0.13    \< 0.05
  Hypertension (no = 0, yes = 1)             0.03    0.631
  Systolic blood pressure                    0.09    0.158
  Diastolic blood pressure                   0.02    0.700
  Dyslipidemia (no = 0, yes = 1)             0.04    0.527
  Fasting blood glucose                      0.05    0.448
  HOMA-IR                                    0.06    0.372
  Hemoglobin A1c                             0.16    \< 0.01
  Heart valvular disease (no = 0, yes = 1)   0.05    0.433
  IVSTd                                      0.04    0.523
  LVDd                                       0.03    0.563
  LVEF                                       0.04    0.514
  LAD                                        0.12    \< 0.05
  E/e′                                       0.30    \< 0.001
  eGFR                                       -0.16   \< 0.01
  Log-BNP                                    0.29    \< 0.001
  Log-hs-cTnT                                0.45    \< 0.001
  d-ROMs test                                0.31    \< 0.001
  CAVI                                       0.38    \< 0.001
  Sulfonylurea (no = 0, yes = 1)             0.03    0.684
  Biguanide (no = 0, yes = 1)                0.04    0.507
  DPP-4 inhibitor (no = 0, yes = 1)          -0.07   0.242
  Insulin (no = 0, yes = 1)                  0.02    0.811
  RAS inhibitor (no = 0, yes = 1)            -0.09   0.158
  β-blocker (no = 0, yes = 1)                0.05    0.429
  Diuretics (no = 0, yes = 1)                0.03    0.679
  Statin (no = 0, yes = 1)                   -0.02   0.701

r expressed correlation coefficient. HOMA-IR: homeostasis assessment insulin resistance; IVSTd: interventricular septal thickness at end-diastole; LVDd: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LAD: left atrial dimension; eGFR: estimated glomerular filtration rate; BNP: brain natriuretic peptide; hs-cTnT: high-sensitivity cardiac troponin T; d-ROMs: derivatives of reactive oxygen metabolites; CAVI: cardio-ankle vascular index; DPP: dipeptidyl peptidase; RAS: renin-angiotensin system.

###### Multiple Regression Analysis for Skin AF

  Explanatory factor   β       P value
  -------------------- ------- ----------
  Log-hs-cTnT          0.30    \< 0.001
  E/e′                 0.25    \< 0.001
  HF hospitalization   0.23    \< 0.001
  CAVI                 0.21    \< 0.001
  d-ROMs test          0.15    \< 0.01
  Age                  0.13    \< 0.05
  eGFR                 -0.08   0.144

R^2^ = 0.31. AF: autofluorescence; hs-cTnT: high-sensitivity cardiac troponin T; CAVI: cardio-ankle vascular index; HF: heart failure; d-ROMs: derivatives of reactive oxygen metabolites; eGFR: estimated glomerular filtration rate; β: standardized regression coefficient; R^2^: coefficient of determination.

![Results of multiple logistic regression analysis of heart failure hospitalization or high hs-cTnT levels. (a) Subordinate factor is heart failure hospitalization. Adjustment factors are hs-cTnT, E/e′, CAVI, d-ROMs test, and age. (b) Subordinate factor is high hs-cTnT levels. High hs-cTnT was defined as hs-cTnT ≥ 0.018 ng/mL. Adjustment factors are E/e′, history of heart failure hospitalization, CAVI, d-ROMs test, and age. \*P \< 0.05 vs. skin AF ≤ 2.5 AU; \*\*P \< 0.01 vs. skin AF ≤ 2.5 AU, \*\*\*P \< 0.001 vs. skin AF ≤ 2.5 AU. hs-cTnT: high-sensitivity cardiac troponin T; CAVI: cardio-ankle vascular index; d-ROMs: derivatives of reactive oxygen metabolites; AU: arbitrary units.](cr-09-083-g002){#F2}

Discussion {#s5}
==========

Ruigomez et al reported that patients hospitalized with an initial HF diagnosis or those hospitalized due to HF thereafter are at high risk of worse outcomes \[[@R19]\]. In addition, some researchers have observed that patients with DM with a history of hospitalization due to HF had poor prognosis compared with patients without diabetes with a history of hospitalization due to HF \[[@R20]\]. Thus, these reports indicated that early diagnosis or intervention therapy for patients with CHF is important to prevent hospitalization due to HF, particularly in patients with diabetes and CHF. In this study targeting patients with type 2 DM with CHF, the skin AF levels in patients with a history of hospitalization due to HF were significantly higher than in those without. Furthermore, a history of hospitalization due to HF was independently associated with skin AF levels. Thus, skin AF levels were considered as an important target factor to define the prognosis of patients with type 2 DM with CHF.

Hs-cTnT is used as a biomarker to evaluate the degree of myocardial injury in clinics. In addition, some clinical studies have shown the clinical usefulness of hs-cTnT as a prognostic value in patients with CHF \[[@R21], [@R22]\]. On the contrary, Hofmann et al reported on the relationship between AGE-modified cardiac tissue collagen levels and skin AF and found a significant relationship between cardiac tissue glycation and skin AF \[[@R23]\]. Their report also indicated that the AGE levels found at the volar side of the lower arm seem to reflect the degree of AGE accumulation in the cardiomyocytes. Some researchers have indicated several pathways wherein AGEs or receptors of AGEs (RAGEs) could influence myocardial injury in a diabetes model. Ma et al \[[@R24]\] reported that DM resulted in a significant increase in AGE and RAGE levels in the heart, particularly in the cardiomyocytes, when using mice with streptozotocin-induced DM. They also reported that AGE-induced cardiomyocyte dysfunction was linked to mitochondrial membrane depolarization and reduced GSK-3β inactivation, which are events that can be prevented by RNA interference knockdown of RAGE expression. In addition, Bucciarelli et al indicated that RAGE affected ischemia/reperfusion injury in the diabetic myocardium \[[@R25]\]. On the contrary, recent clinical studies noted the importance of left ventricular diastolic dysfunction in the pathogenesis of HF. Furthermore, some researchers have indicated that AGEs or RAGE affected left ventricular diastolic function \[[@R26], [@R27]\]. Wang et al reported the significant relationship of E/e′ as a marker of left ventricular diastolic function and skin AF in subjects at risk for cardiovascular diseases \[[@R28]\]. The results of these studies also indicate that skin AF levels reflect left ventricular diastolic function in patients with type 2 DM with CHF. Thus, the results of this study and those of previous studies have shown that AGEs and RAGEs are believed to play important roles in myocardial injury or left ventricular diastolic dysfunction in patients with type 2 DM with CHF.

A number of studies have shown the importance of oxidative stress in the pathogenesis of CHF. Several pathways wherein oxidative stress leads to myocardial injury have been reported, including dysfunction of the mitochondrial electron transport complex, nicotinamide adenine dinucleotide phosphate oxidase activity, and myocardial cell apoptosis \[[@R29], [@R30]\]. In contrast, a number of basic and clinical studies have shown a close association between AGEs or RAGEs and oxidative stress. In addition, an association between AGEs or RAGEs and oxidative stress in myocardial cells has been reported \[[@R31]\]. In this study, a significant correlation was observed between skin AF and d-ROM test as a marker of oxidative stress *in vivo*, suggesting that AGEs or RAGEs and oxidative stress are associated with each other in myocardial cells, and this consequently promotes myocardial injury in patients with type 2 DM with CHF.

In this study, CAVI as one of the physiological markers of arterial function was independently associated with skin AF levels. Basic studies have reported that AGEs or RAGE can induce inflammation, oxidative stress, and calcification in vascular cells, such as endothelial or smooth muscle cells \[[@R32]-[@R34]\]. Clinical studies have also indicated a significant association between skin AF and physiological markers of arterial function, including CAVI \[[@R35]-[@R37]\]. On the contrary, some researchers have shown the importance of arterial function in the pathogenesis of CHF \[[@R38], [@R39]\]. Skin AF as a marker of AGE levels *in vivo* is thus considered as a considerable risk factor for progression of CHF, not only in direct influence for cardiomyocytes but also in arterial function.

Setting a target value for predicting adverse cardiovascular events in the clinical setting would be useful. In this study, the participants were divided into three groups based on the simple cut-off of values of skin AF levels to clarify the clinical significance of skin AF measurements in patients with type 2 DM with CHF, and multiple logistic regression analysis was performed to detect a correlation between hospitalization due to HF or high hs-cTnT levels (≥ 0.018 ng/mL), which has been reported as being the cut-off level for predictive cardiovascular incidence rate in patients with CHF \[[@R22]\]. The results of this study have indicated that patients with skin AF values ≥ 3.0 or from 2.6 - 2.9 exhibited a significantly higher risk of hospitalization due to HF and higher hs-cTnT levels than did those with skin AF values ≤ 2.5. Thus, the results of this study suggest using the cut-off skin AF level of 3.0 or 2.5 to prevent adverse cardiovascular events in patients with type 2 DM with CHF. In contrast, Yamagishi et al reported that AGEs are considered to be markers expressing hyperglycemic memory \[[@R40]\]. Genevieve et al performed a study regarding the association between skin AF and HbA1c levels, and they reported that skin AF level was significantly associated with the means of the last five and 10 HbA1c values \[[@R41]\]. Thus, these reports have shown that we should perform long-term glucose control to prevent adverse cardiovascular events in patients with type 2 DM with CHF.

Limitations {#s5a}
-----------

This study has several limitations. First, the medical treatments for DM, CHF, hypertension, and/or dyslipidemia may have affected the study results. Second, the HOMA-IR has limitations as a marker of insulin resistance, particularly in patients with high blood glucose levels, and we included patients with high fasting blood glucose levels. Therefore, additional studies using another accurate insulin resistance marker, such as a glucose clamp test, are warranted to evaluate the clinical significance of insulin resistance in this study design. Third, not every patient underwent coronary angiography or coronary artery computed tomography. Therefore, asymptomatic ischemic heart disease may have remained undetected. Finally, the study design was a single-center cross-sectional study and the sample size was relatively small. Additional prospective studies, including evaluations of interventional therapies, are required to clarify the clinical significance of skin AF in patients with type 2 DM with CHF.

Conclusions {#s5b}
-----------

The findings of this study showed that skin AF may be a determining factor for prognosis of patients having type 2 DM with CHF. Further investigations in many prospective studies, including intervention therapies, are required to validate the results of this study.
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